Profil
Nelson Chau worked as a Vice President at LogicBio Therapeutics, Inc. from 2017 to 2021.
Prior to that, he worked as a Vice President at Translate Bio, Inc. and as a Director of Research at Regulus Therapeutics, Inc. Mr. Chau holds a doctorate degree from The Johns Hopkins University School of Medicine.
Anciens postes connus de Nelson Chau
| Sociétés | Poste | Fin |
|---|---|---|
| LOGICBIO THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/05/2021 |
| REGULUS THERAPEUTICS INC. | Directeur Technique/Scientifique/R&D | - |
| TRANSLATE BIO, INC. | Corporate Officer/Principal | - |
Formation de Nelson Chau
| The Johns Hopkins University School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| REGULUS THERAPEUTICS INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
LogicBio Therapeutics, Inc.
 LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology LogicBio Therapeutics, Inc. engages in the development of a genome editing technology platform. It focuses on the commercialization of GeneRide, which enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. Its pipeline includes LB-001, LB-301 and LB-401. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Lexington, MA. | Health Technology |
Translate Bio, Inc.
 Translate Bio, Inc. BiotechnologyHealth Technology Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidate, MRT5005 is designed for the treatment of cystic fibrosis. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA. | Health Technology |
